Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial - Archive ouverte HAL Access content directly
Journal Articles BMJ Open Year : 2018

Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial

(1, 2) , (3) , (4, 5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (9) , (2) , (13) , (14) , (15) , (16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Tristan Ferry
  • Function : Author
  • PersonId : 844016
François Vandenesch
Xavier Marie Duval
  • Function : Author
  • PersonId : 857490

Abstract

Introduction Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is a common and severe disease responsible for approximately 65,000 deaths every year in Europe. Intravenous anti-staphylococcal penicillins (ASP) such as cloxacillin are the current recommended antibiotics. However, increasing reports of toxicity and recurrent stock-outs of ASP prompted healthcare providers to seek for alternative antibiotic treatment. Based on retrospective studies, cefazolin, a 1st generation cephalosporin, is recommended in patients at risk of severe ASP-associated toxicity. We hypothesized that cefazolin has a non-inferior efficacy in comparison to cloxacillin, with a better safety profile for the treatment of MSSA bacteremia. Methods and analysis The CloCeBa trial is an open-label, randomized, controlled, non-inferiority trial conducted in academic centers throughout France. Eligible patients are adults with MSSA bacteremia without intra-vascular device or suspicion of central nervous system infection. Patients will be randomized (1:1) to receive either cloxacillin or cefazolin by the intravenous route, for the first 14 days of therapy. The evaluation criteria is a composite criteria of negative blood cultures at day 5, survival, absence of relapse, and clinical success at day 90 after randomization. Secondary evaluation criteria include both efficacy and safety assessments. Three ancillary studies are planned to describe the epidemiology of β-lactamase encoding genes, the ecological impact, and pharmacokinetic/pharmacodynamic parameters of cefazolin and cloxacillin. Including 300 patients will provide 80% power to demonstrate the non-inferiority of cefazolin over cloxacillin, assuming 85% success rate with cloxacillin and taking into account loss-to-follow-up, with a 0.12 non-inferiority margin and a one-sided type I error of 0.025. Ethics and dissemination This protocol received authorization from the ethics committee Sud-Est I on November, 13th 2017 (2017-87-PP). Results will be disseminated to the scientific community through congresses and publication in peer-reviewed journals. Trial registration This trial is registered on clinicaltrial.gov (NCT03248063) and on Eudract (2017-003967-36) databases.
Fichier principal
Vignette du fichier
Cloceba_protocole_publi_HAL.pdf (649.92 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-01920063 , version 1 (21-05-2019)

Identifiers

Cite

Charles Burdet, Paul Loubet, Vincent Le Moing, William Vindrios, Marina Esposito-Farèse, et al.. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. BMJ Open, 2018, 8 (8), pp.e023151. ⟨10.1136/bmjopen-2018-023151⟩. ⟨inserm-01920063⟩
134 View
471 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More